230 related articles for article (PubMed ID: 35753891)
1. Cardiovascular Morbidity and Mortality in Men - Findings From a Meta-analysis on the Time-related Measure of Risk of Exogenous Testosterone.
Fallara G; Pozzi E; Belladelli F; Corsini C; Boeri L; Capogrosso P; Montorsi F; Salonia A
J Sex Med; 2022 Aug; 19(8):1243-1254. PubMed ID: 35753891
[TBL] [Abstract][Full Text] [Related]
2. Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies.
Corona G; Rastrelli G; Di Pasquale G; Sforza A; Mannucci E; Maggi M
J Sex Med; 2018 Jun; 15(6):820-838. PubMed ID: 29803351
[TBL] [Abstract][Full Text] [Related]
3. Testosterone Therapy and Risk of Acute Myocardial Infarction in Hypogonadal Men: An Administrative Health Care Claims Study.
Li H; Mitchell L; Zhang X; Heiselman D; Motsko S
J Sex Med; 2017 Nov; 14(11):1307-1317. PubMed ID: 29110802
[TBL] [Abstract][Full Text] [Related]
4. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study.
Haider A; Yassin A; Haider KS; Doros G; Saad F; Rosano GM
Vasc Health Risk Manag; 2016; 12():251-61. PubMed ID: 27366080
[TBL] [Abstract][Full Text] [Related]
5. Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk.
Khera M; Miner M; Jaffe J; Pastuszak AW
J Sex Med; 2021 Jan; 18(1):83-98. PubMed ID: 33317996
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data.
Alwani M; Yassin A; Talib R; Al-Qudimat A; Aboumarzouk O; Al-Zoubi RM; Saad F; Haider KS; Al Ansari A
Vasc Health Risk Manag; 2021; 17():497-508. PubMed ID: 34465997
[TBL] [Abstract][Full Text] [Related]
7. Obstructive Sleep Apnea Is Associated With Polycythemia in Hypogonadal Men on Testosterone Replacement Therapy.
Lundy SD; Parekh NV; Shoskes DA
J Sex Med; 2020 Jul; 17(7):1297-1303. PubMed ID: 32307242
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality.
Saad F; Caliber M; Doros G; Haider KS; Haider A
Aging Male; 2020 Mar; 23(1):81-92. PubMed ID: 30782054
[No Abstract] [Full Text] [Related]
9. Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms.
Saad F; Doros G; Haider KS; Haider A
Investig Clin Urol; 2018 Nov; 59(6):399-409. PubMed ID: 30402573
[TBL] [Abstract][Full Text] [Related]
10. Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism.
Grabner M; Hepp Z; Raval A; Tian F; Khera M
J Sex Med; 2018 Feb; 15(2):148-158. PubMed ID: 29425664
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control) Groups.
Traish AM; Haider A; Haider KS; Doros G; Saad F
J Cardiovasc Pharmacol Ther; 2017 Sep; 22(5):414-433. PubMed ID: 28421834
[TBL] [Abstract][Full Text] [Related]
12. Controversies in Testosterone Therapy.
Twitchell DK; Pastuszak AW; Khera M
Sex Med Rev; 2021 Jan; 9(1):149-159. PubMed ID: 33309270
[TBL] [Abstract][Full Text] [Related]
13. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism.
Pencina KM; Travison TG; Cunningham GR; Lincoff AM; Nissen SE; Khera M; Miller MG; Flevaris P; Li X; Wannemuehler K; Bhasin S
J Clin Endocrinol Metab; 2024 Jan; 109(2):569-580. PubMed ID: 37589949
[TBL] [Abstract][Full Text] [Related]
14. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
Honig S; Gittelman M; Kaminetsky J; Wang C; Amory JK; Rohowsky N; Dudley RE; Woun Seo B; Newmark J; Swerdloff R
J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.
Corona G; Rastrelli G; Morgentaler A; Sforza A; Mannucci E; Maggi M
Eur Urol; 2017 Dec; 72(6):1000-1011. PubMed ID: 28434676
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from a controlled registry study.
Saad F; Doros G; Haider KS; Haider A
Int J Obes (Lond); 2020 Jun; 44(6):1264-1278. PubMed ID: 32060355
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome.
Hackett G
Sex Med Rev; 2019 Jul; 7(3):476-490. PubMed ID: 30803918
[TBL] [Abstract][Full Text] [Related]
18. The Role of Testosterone Therapy in the Setting of Prostate Cancer.
Rodriguez KM; Pastuszak AW; Khera M
Curr Urol Rep; 2018 Jun; 19(8):67. PubMed ID: 29961247
[TBL] [Abstract][Full Text] [Related]
19. Controversies with testosterone therapy.
Khera M
Can J Urol; 2020 Aug; 27(S3):20-23. PubMed ID: 32875998
[TBL] [Abstract][Full Text] [Related]
20. Testosterone treatment and change of categories of the International prostate symptom score (IPSS) in hypogonadal patients: 12 years prospective controlled registry study.
Yassin A; Kelly D; Nettleship J; Talib R; Al-Zoubi RM; Aboumarzouk OM; Albaba B
Aging Male; 2023 Dec; 26(1):2220567. PubMed ID: 37287273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
